NeoGenomics Reports Q2 2025 Earnings with Revenue Growth and Mixed Performance
NeoGenomics (NEO) reported Q2 2025 earnings with total revenue of $181 million, a 10% year-over-year increase, though slightly below guidance. Clinical revenue rose 16% year-over-year, while nonclinical revenue fell 26% due to weak demand in pharma and biotech. NGS testing grew 23% year-over-year, but missed internal targets.
Topics: AUP Clinical Revenue Earnings EBITDA Gross Profit NGS Growth Nonclinical Revenue Revenue Test Volume